During the three and nine months ended September 30, 2026, we recognized $0.4 million and $1.3 million, respectively, of compensation expense associated with stock option and restricted stock awards granted in years 2021 through 2026. During the three and nine months ended September 30, 2025, we recognized $0.4 million and $1.2 million, respectively, of compensation expense associated with stock option and restricted stock awards granted in years 2020 through 2025.

The following table summarizes our stock option activity for the nine-month period ended September 30, 2026:


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
		Exercise		Contractual	Value*
Stock Options	Shares	Price		Term (In Years)	(In Thousands)
Outstanding at January 1, 2026	512,705	$	26.15
Granted	—		—
Exercised	(176,730)		26.12
Forfeited or expired	(9,090)		29.24
Outstanding at September 30, 2026	326,885	$	26.07	5.0	$	7,302
Exercisable at September 30, 2026	252,989	$	25.87	4.6	$	5,702

*The aggregate intrinsic value of outstanding and exercisable stock options is defined as the difference between the market value of our Company’s common stock on September 30, 2026 of $48.41 and the exercise price multiplied by the number of in-the-money outstanding and exercisable stock options.

The following table summarizes our restricted stock award activity for the nine-month period ended September 30, 2026:


					Weighted
			Weighted		Average		Aggregate
		Shares of	Average		Remaining		Intrinsic
		Restricted	Grant Date		Contractual		Value*
Restricted Stock		Stock	Fair Value		Term (In Years)		(In Thousands)
Non-vested - January 1, 2026		120,539	$	31.06
Granted		47,846		45.58
Vested		(41,834)		30.86
Forfeited		(6,036)		34.50
Non-vested - September 30, 2026		120,515	$	30.90	3.9	$	5,834

*The aggregate intrinsic value of non-vested restricted stock was calculated using the market value of our Company’s common stock on September 30, 2026 of $48.41 multiplied by the number of non-vested restricted shares outstanding.